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Abstract
The Src family kinases (SFK) are a group of signalling molecules with important regu-
latory functions in inflammation and haemostasis. Leucocytes and platelets express
multiple isoforms of the SFKs. Previous studies used broad-spectrum pharmacologi-
cal inhibitors, or murine models deficient in multiple SFK isoforms, to demonstrate
the functional consequences of deficiencies in SFK signalling. Here, we hypothesized
that individual SFK operate in a non-redundant fashion in the thrombo-inflammatory
recruitment of monocyte during atherosclerosis. Using in vitro adhesion assays and
single SFK knockout mice crossed with the ApoE/ model of atherosclerosis, we
find that SFK signalling regulates platelet-dependent recruitment of monocytes.
However, loss of a single SFK, Fgr or Lyn, reduced platelet-mediated monocyte
recruitment in vitro. This translated into a significant reduction in the burden of
atherosclerotic disease in Fgr//ApoE/ or Lyn//ApoE/ animals. SFK signalling
is not redundant in thrombo-inflammatory vascular disease and individual SFK may
represent targets for therapeutic intervention.
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1 | INTRODUCTION
Primary atherosclerosis is a chronic inflammatory, fibro-proliferative
disease of the artery wall, in which arterial plaques of great cellular
and molecular complexity develop over many years.1 The recruit-
ment of inflammatory leucocytes from the blood into the artery wall
occurs at all stages of the disease and this process is widely assumed
to be dependent upon the well-documented multi-step paradigm of
leucocyte trafficking that supports leucocyte recruitment in the post-
capillary venules during acute, resolving inflammatory responses.2
However, in atherosclerosis there is strong evidence that alternative
thrombo-inflammatory pathways of leucocyte trafficking are
provided by interactions between platelets, leucocytes and vascular
endothelial cells.3-6 In the context of the therapeutic control of
inflammation in atherosclerosis, these alternative pathways are
important, as they bypass the usual regulatory mechanisms that con-
trol the magnitude and duration of the inflammatory response. This
makes it difficult to target leucocyte recruitment in atherosclerosis
using current anti-inflammatory strategies. However, the provision of
distinct molecular and signalling pathways that support platelet-
mediated leucocyte accumulation in atherosclerosis provides an
opportunity to develop new, disease specific, drugs.
The expression of P-selectin on activated platelets is reported to
be important for establishing adhesive contact with circulating leuco-
cytes.7 Thus, an obvious target for intervening in thrombo-inflamma-
tory leucocyte trafficking is the inhibition of platelet activation.
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However, patients at high risk of cardiovascular disease are already
well served by antiplatelet agents such as aspirin and the antagonists
of the ADP receptor P2Y12 (eg Prasugrel and Ticagralor).8-10
Although these show anti-inflammatory activity over and above their
ability to prevent thrombosis,11,12 their use does not prevent pro-
gression of atherosclerosis in humans.13 Thus, we require a different
approach to target thrombo-inflammatory pathways with greater
precision. We believe that targeting signalling pathways involved in
the activation and function of both platelets and leucocytes repre-
sent tractable targets for such interventions, and the Src family
kinases (SFKs) may be appropriate due to their importance in regu-
lating the function of both cell types.
In mammals, SFKs are a group of 8 structurally related protein
tyrosine kinases.14 Src, Fyn and Yes are ubiquitously expressed,15
although distinct isoforms dominate expression in different cells.16-18
Lyn, Hck, Fgr, Blk and Lck however, are predominantly and differen-
tially expressed in the various cells types of the haematopoietic lin-
eage, ie leucocytes and platelets.19 Leucocyte SFKs play an
important role in the regulation of many activation responses, but
they are considered particularly important during the development
of an inflammatory response. In particular, leucocyte recruitment by
cytokine-activated endothelial cells, resulting in integrin-mediated
leucocyte activation and migration in to tissue, is an essential pro-
cess in the inflammatory response. Although non-redundant func-
tions of Fyn have been identified in neuronal maturation and spatial
learning in knockout animals,20,21 leucocytes deficient in multiple
SFK have been presumed necessary to remove redundant SFK sig-
nalling during leucocyte recruitment in inflammation. Such a strategy
inhibits the function multiple adhesion pathways, including the b1
and b2 integrins essential for leucocyte trafficking.22-24 In addition,
leucocyte functions that may be dependent on outside-in signals
originating from ligand bound integrins are also affected in SFK-defi-
cient animals.25,26 For example, initiation of the respiratory burst,
degranulation and phagocytosis are known to be impaired in the
absence of SFK signalling.27,28 SFK are also essential for platelet
activation. They mediate rapid activation down stream of adhesion
receptors such as GPIb-IX-V (von Willebrand receptor29) and GPVI
(collagen receptor30), they promote maximal platelet activity by sig-
nalling downstream of G-coupled receptors for secondary mediators
such as ADP,31 and they regulate outside-in signals from extra-cellu-
lar matrix binding integrins such aIIbb3, required for efficient activa-
tion, spreading, secretion and clot retraction.32
Importantly however, the roles of SFK in thrombo-inflammatory
pathways of leucocyte recruitment have not been investigated to
date. Here, we show that the platelet-dependent recruitment of
monocytes in in vitro models of vascular inflammation was strongly
dependent upon SFK’s in both murine and human systems. Using
genetically modified mice in which the most (Lyn) and least (Fgr)
abundant platelet SFK isoforms had been knocked out independently,
the platelets of both Fgr/ and Lyn/ deficient animals showed
greatly retarded activation responses to ADP in vitro. When these
platelets were used in functionally stringent thrombo-inflammatory
models of leukcoyte recruitment in vitro, both strains showed
significant deficiencies in leucocyte recruitment. We also observed
dramatic reductions in the burden of disease in the Fgr//ApoE/
and Lyn//ApoE/ models of atherosclerosis.
2 | MATERIALS AND METHODS
2.1 | Animals
Fgr/ApoE/ and Lyn/ApoE/ mice on a C57BL6 background
were generated from ApoE/ (Charles River), Lyn/ (Jackson Labo-
ratoy) and Fgr/ (Prof Clifford Lowell, UCSF, San Francisco, USA)
animals. All mice were maintained at the Biomedical Services Unit at
the University of Birmingham, according to Home Office regulations.
Mice were genotyped using the DNeasy blood and tissue kit (Qia-
gen, Germany), according to manufacturer’s instructions. Age and
sex matched Fgr/ApoE/, Lyn/ApoE/ and ApoE/ mice were
maintained on chow diet between weaning and 6 weeks. At
6 weeks, the mice were placed on a high fat diet (HFD) (21.4%
cocoa butter [w/w] and 0.2% cholesterol [w/w]; Special Diet Ser-
vices, UK) for 6 weeks. We observed no sex differences in our anal-
ysis so both male and female data were included.
2.2 | Murine blood collection for in vitro studies
Murine blood was drawn by cardiac puncture from mice terminally
anesthetized with CO2 and taken into 100 lL sodium citrate and
combined with 200 lL modified Tyrode buffer (137 mmol/L NaCl.
11.9 mmol/L NaHCO3, 0.4 mmol/L Na2HPO4, 2.7 mmol/L KCl,
1.1 mmol/L MgCl2, 20 mmol/L Hepes and 5.6 mmol/L glucose, pH
7.3). Blood was left at room temperature until further processing.
2.3 | Murine hematological and serum lipid analysis
Total white blood cell (WBC) counts and differential white cell
counts were determined using the ABX Pentra 60 hematology analy-
ser (Horiba, Northampton, UK). Non-anticoagulated blood was
allowed to clot at room temperature for 1 hour then centrifuged at
20 000 g for 10 minutes. Serum was collected and stored at 20°C.
Serum triglyceride (Randox, Antrim, UK), free fatty acids (Abcam,
Cambridge, UK), total cholesterol levels, HDL, LDL and glucose (Sen-
tinel Diagnostics, Milan, Italy) were analysed via colorimetric assays.
2.4 | Murine aorta isolation
Mice were sacrificed via terminal intraperitoneal (IP) injection of
200 mg/kg Pentobarbital. Aortas were fixed in situ by the perfusion
of 2% paraformaldehyde (Sigma, UK) through the left ventricle of
the heart. The whole aorta was excised, cut longitudinally and
stained with Oil Red O (ORO; Sigma). Digital photographs were
taken and analyzed for lesion size, as a percentage of a specific
region (whole aorta, inner and outer curvature, aortic arch, aortic
branches, thoracic and abdominal aorta), using ImageJ software (NIH,
USA). Detailed analysis of plaque burden in the descending aorta
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was conducted in order to evaluate the total number and average
size of plaques in an area of the aorta which has several branch
points (intercostals, mesenteric and renal arteries). Digital images
were analysed in ImageJ software (NIH) via threshold analysis. Indi-
vidual plaques were analysed with a threshold of 0.5 mm2 and circu-
larity of 0.04 mm.
2.5 | Histology and immunofluorescence
microscopy of atherosclerotic lesions in frozen
sections
Lesion stability and morphology was assessed in OCT-embedded
frozen aortic root sections, which had been previously perfusion
fixed with 4% paraformaldehyde. The aortic root was sectioned at
20°C at 7 lm per section. To quantify collagen content sections
were stained with van Gieson’s (Merck, Germany) according to the
manufacturer’s instructions. Staining with DAPI was also utilized to
quantify cellular content within the plaque. All images were anal-
ysed with ImageJ software via threshold analysis. Van Gieson
stained aortic arch sections were imaged using the Axio ScanZ1
(Zeiss, Germany) at 920 magnification and DAPI-stained sections
were imaged using the Olympus BX61 Upright Motorized Micro-
scope (Olympus, Japan) at 94 magnification. Plaque collagen con-
tent and cellularity analysis was carried out using Fiji (NIH). Once
imaged, tissue sections had masks applied over plaques within the
aortic arches and the area quantified before and after applying a
colour threshold selection for red pixels (red denotes collagen posi-
tivity using Van Gieson). Total plaque area pixel counts and total
plaque red pixel counts were used to calculate % collagen positivity
within plaques. In order to quantify the cellularity within plaques,
the integrated density of DAPI staining was measured after manual
selection of plaques within aortic arch sections from ApoE/,
ApoE/Lyn/ and ApoE/Fgr/ mice.
2.6 | Human blood collection for in vitro studies
Venous blood from healthy volunteers was taken into 10% sodium
citrate or EDTA.
2.7 | Preparation of platelet rich plasma
Platelet-rich plasma (PRP) was obtained from human and murine
anti-coagulated blood by addition of modified Tyrode’s buffer 1:5 to
volume of whole blood and centrifugation at 3009 g for 10 minutes.
PRP was then removed and diluted to the required concentration
with Tyrode’s/Hepes buffer.
2.8 | Peripheral blood mononuclear cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
human EDTA treated blood using the histopaque 1119 and 1077
gradient system (Sigma). Murine PBMCs were isolated using Lym-
pholyte Mammal (Cedarlane Laboratorys). Briefly, 2 mL of EDTA
treated Blood was diluted 1:1 with PBS and layered over 5 mL of
Lympholyte mammal and centrifuged at 8009 g for 20 minutes at
room temperature. PBMC layer was removed and diluted to 10 mL
with PBS and centrifuged at 8009 g for 10 minutes at room temper-
ature to pellet cells. Supernatant was removed and PBMCs were
diluted to 1 9 106 cells/mL in PBS.
2.9 | Aggregometry
Platelet aggregation was monitored in 300 lL (2 9 108 /mL) PRP.
Aggregation was monitored by light transmission using a Born aggre-
gometer (Alpha Laboratories, Eastleigh, Hants, UK) with high-speed
stirring (1200 rpm) at 37°C. Agonists were added as 10-100-fold
concentrates. The transmission with PRP was expressed as a
percentage of that with platelet-poor plasma.
2.10 | Flow cytometry analysis of P-selectin
expression
Platelet-rich plasma was extracted as previously described. 5 lL PRP
was added to 45 lL Tyrode’s buffer. Platelets were incubated with
5 lL CD41 Allophycocyanin (APC), (Human-BD, 559777 & Mouse-
ebioscience, 17-0411-82) and CD62P Fluorescein (FITC), (Human-
BD, 555523 & Mouse-Emfret, M130-1) and incubated at 37°C for
30 minutes  30 lmol/L ADP, Dasatinib (LC Laboratories, Woburn,
MA, USA) and/or 0.1% DMSO. The reaction was then stopped with
the addition of 1% ice cold formalin and analysed on a BD Accuri
using C6 software (version 1.0.264.21).
2.11 | Human flow-based adhesion assay on VWF
Blood was collected as previously described. Capillary tubes1
(0.1 9 1.0 mm, 50 mm long; Camlab, Cambridge, UK) were coated
with 0.1 mg/mL human Von Willebrand factor (VWF) (HTI, Vermont,
USA-HCVWF-0190) overnight at 4°C. The capillaries were washed
and blocked with PBS containing 2% BSA (PBSA) for 2 hours at
room temperature. Capillaries were then rinsed with PBSA, and con-
nected to a multi-valve flow-based system containing reservoirs
filled with either anti-coagulated blood, PBMCs or PBSA. The anti-
coagulated blood was perfused through the VWF-coated microcapil-
lary at a shear rate of 1000s for 2 minutes. Capillaries were then
washed with 0.1% PBSA (30 lmol/L ADP) at 1000s, before
PBMCs were perfused. Platelet/monocyte adhesion was monitored
at 100s by phase contrast microscopy. At least 6 different micro-
scope fields (209 objective) were analysed. Image analysis was per-
formed off-line using ImagePro plus software (DataCell Limited,
Berkshire, UK).
2.12 | Murine flow-based adhesion assay on VWF
Blood was collected as previously described. Capillary tubes
(0.1 9 1.0 mm, 50 mm long; Camlab) were coated with 3.1 g/L
anti-Human VWF (Dako, Cambridge, UK—A0082) overnight at
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4°C. The capillaries were washed and blocked with PBS containing
2% BSA for 1 hour at room temperature, followed by murine
plasma for 1 hour at room temperature. Capillaries were then con-
nected to a multi-valve flow-based system containing reservoirs
filled with either anti-coagulated blood, PBMCs or PBSA. The
anti-coagulated blood was perfused through the VWF-coated
microcapillary at a shear rate of 1000s for 2 minutes. Capillaries
were then washed with PBSA (30 lmol/L ADP) at 1000s,
before PBMCs were perfused. Platelet/monocyte adhesion was
monitored at 100s by phase contrast microscopy. At least 6 dif-
ferent microscope fields (20 9 objective) were analysed. Image
analysis was performed off-line using ImagePro plus software
(DataCell Limited).
2.13 | Isolation and culture of Human Endothelial
cells
Human umbilical vein endothelial cells (HUVEC) were isolated and
characterized as described previously.33 Each experiment used first
passage ECs from a different donor and cells were cultured on
APES-coated glass capillary microslides. EC cultures in microslides
were either untreated or stimulated with 10 ng/mL TGF-b1 for
24 hours.
2.14 | Reagents
Dasatinib (LC Laboratories) was dissolved in dimethyl sulfoxide
(DMSO) at a stock concentration of 1 mmol/L. Final concentrations
of 20 lmol/L (0.1% DMSO) were used in all experiments. DMSO
was included in all assays as a solvent control.
2.15 | Statistical analysis
Experimental data were analysed using GraphPad Prism software
(GraphPad, La Jolla, USA-version 5) or SPSS (IBM). Normality of
data was checked using the Shapiro-Wilk normality test when
n ≤ 10 or the D’Agostino & pearson normality test when n ≥ 10.
Non-parametric tests were used when the data did not pass the
normality tests. Differences between individual treatments or
groups were analysed by paired or unpaired t test as appropriate.
One or two-way analysis of variance (ANOVA) was used for multi-
ple group comparison followed by a post hoc analysis where
appropriate, using Bonferroni test for comparisons between groups
or Dunnet tests for comparisons to a control group. P values of
≤.05 were considered significant. Data are expressed as mean 
standard error of the mean (SEM) when n ≥ 8 or standard devia-
tion (SD) when n ≤ 8.
2.16 | Study approval
Animal studies were conducted under Home Office licence PPL 400
3659. Samples from healthy human volunteers were conducted fol-
lowing ethical approval (Birmingham University Research Ethics
Committee, Birmingham, UK) and according to the Declaration of
Helsinki Principles. All participants gave their written informed
consent before samples were taken.
3 | RESULTS
3.1 | SFK are required for thrombo-inflammatory
recruitment of leucocytes in in vitro models of
vascular inflammation
Studies using broad spectrum inhibitors of SFK function, such as
Dasatanib or PP2, show that removal of redundant SFK signalling
can efficiently ablate the activation of platelets using in vitro
assays such as platelet aggregometry.31 Here, we confirm that
Dasatnib is an efficient inhibitor of the aggregation of both human
and murine platelets (Supporting information Figure S1A-F). The
loss of single SFK isoforms using genetically altered strains of
mice (specific inhibitors have yet to be developed to allow phar-
macological intervention in a SFK isoform-specific manner) pre-
sents a different picture. Uniformly, such studies report little if
any effect of the loss of single SFK isoforms on platelet function
in aggregometry assays, and the animals present with a mild, if
any, bleeding diathesis, when the haemostatic system is tasked
in vivo.32,33 However, studying the aggregation of purified plate-
lets in stirred suspensions has no physiological correlate, and
induction of efficient aggregation requires high levels of agonist.
Indeed, in our own experiments we saw little effect of the genetic
ablation of the single SFK isoforms, Lyn or Fgr, when platelet
responses were tested in aggregomtery experiments using 10 or
30 lg/mL ADP. However, when we titrated ADP below such con-
centrations (1-5 lg/mL) we were able to see subtle but significant
deficiencies in the aggregation responses of platelets isolated from
either knockout strain (Supporting information Figure S2A,B). The
fact that differences in platelet function were discernible in aggre-
gometry experiments immediately prompted a detailed analysis in
stringent flow-based adhesion assays using physiological substrates
for platelet recruitment. When CPDA anti-coagulated whole blood
was perfused at a wall shear rate of 1000 s1 across VWF immo-
bilized in glass microslides, a large population of rapidly rolling pla-
telets was established. This was the case for human blood
perfused across hVWF (Figure 1A) and for murine blood (Fig-
ure 1B) perfused across mVWF. These interactions were not
stable and after washout of blood, few platelets remained on the
adhesive surface (Figure 1A,B). However, by adding 30 lmol/L
ADP to the wash buffer, adhesion was efficiently stabilized when
the platelets were activated and spread on the adhesive substrate
to provide between 20% and 30% coverage (Figure 1A-D). When
a bolus of isolated monocytes (or mononuclear cells in the murine
system) was perfused (at 100 s1) over unactivated platelets there
was little leucocyte adhesion, demonstrating that VWF was not a
substrate that could promote efficient recruitment of flowing
monocytes in the absence of activated platelets (Figure 1E,F). In
contrast, there was substantial secondary recruitment of
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monocytes to ADP activated platelets as these cells provided an
adhesive bridge between the flowing leucocytes and the VWF
substrate (Figure 1E,F).
When these experiments were conducted in the presence of Dasa-
tinib (20 lmol/L), platelet activation and adhesion were effectively
abolished (>90% inhibition in human and murine-based assays; Fig-
ure 1A,B). Ablation of redundant SFK signalling in platelets had a dra-
matic effect on the secondary recruitment of monocytes. Thus, in both
the human and murine systems, monocyte adhesion was reduced by
90%, which paralleled the loss of platelet coverage (Figure 1E,F).
The loss of monocyte adhesion to the extent observed was surprising,
as we and others have previously shown that even sparsely adherent
platelets (ie <1% coverage) can support substantial levels of leucocyte
tethering and adhesion through P-selectin.6,34 In addition, using this
flow system, we observed that efficient recruitment of human neu-
trophils on platelets bound to VWF (Supporting information Figure S3).
Treatment of whole blood with Dasatinib (20 lmol/L) also significantly
decreased neutrophil adhesion by 89%.
Flow cytometry analysis of platelets activated by ADP in the
presence or absence of dasatanib provided the rationale for the
observed inhibition of monocyte recruitment by the remaining
adherent platelets (2%-5% coverage in the presence of dasatanib).
In both human and murine platelets, dasatanib inhibited the
expression of platelet P-selectin at ADP concentrations as high as
30 lmol/L (Figure 2A-D).
In more stringent cell-based models of vascular inflammation, we
have previously identified TGF-b1 as a potent agonist of VWF
expression on EC. Indeed, TGF-b1 can promote platelet adhesion
and secondary leucocyte recruitment both in vitro6 and in vivo.6
Using an in vitro flow-based assay, we observed that stimulation of
human EC with TGF-b1 (10 ng/mL) resulted in substantial adhesion
of human platelets from flowing whole blood (Figure 2E), which in
turn supported the secondary recruitment of monocytes from the
flowing blood.
Importantly, addition of dasatanib (10 lmol/L) to blood prior to
perfusion across activated EC, significantly reduced platelet coverage
on TGF-b1 stimulated EC. In turn, this had a marked effect on the
efficiency of secondary recruitment of monocytes, resulting in a sig-
nificant reduction in their adhesion (Figure 2E,F).
3.2 | Genetic deletion of single SFK isoforms in
mice alters platelet activation and inhibits the
thrombo-inflammatory recruitment of monocytes
Having demonstrated that the removal of redundant SFK had dra-
matic effects on the thrombo-inflammatory recruitment of
F IGURE 1 Dasatinib inhibits platelet
activation and recruitment of monocytes
on immobilized VWF under flow
conditions. A, Percentage platelet coverage
from flowing human whole blood (1000s)
on a matrix of immobilized VWF in the
presence of 30 lmol/L ADP  20 lmol/L
broad spectrum SFK inhibitor, (B) or using
murine whole blood (n = 3). C,
Representative images of human or (D)
murine platelet adhesion to VWF in the
presence of 30 lmol/L ADP under flow
conditions (1000s). E, Total adhesion of
Human or (F) murine monocytes in the
presence of 30 lmol/L ADP  20 lmol/L
Dasatinib under flow conditions (100s).
The level of monocyte and platelet
adhesion was assessed by phase contrast
microscopy (n = 3). Data are shown as
mean  SD. *P < .05, **P < .01 compared
to the ADP positive control using one-way
ANOVA followed by a Dunnett’s post-test
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leucocytes, we tested whether platelets deficient in single SFK iso-
forms showed any deficit in thrombo-inflammatory activity. Using
whole blood taken from animals with a complete knock out of the
most and least abundant SFK’s in platelets (Lyn and Fgr, respec-
tively), we found that platelets were readily recruited to and rolled
upon immobilized VWF. The number of adherent platelets did not
F IGURE 2 Dasatinib inhibits platelet P-selectin expression in both human and mouse platelets and prevents the adhesion of platelets and
monocytes to TGF-b1 stimulated endothelium under flow conditions. A, Representative flow cytometry plots of P-selectin expression in human
or (B) murine platelet-rich plasma (PRP) prepared from freshly drawn blood and stimulated with 30 lmol/L ADP  20 lmol/L Dasatinib. C,
Mean fluorescent intensity (MFI) of P-selectin staining on human or (D) murine platelets. E, The effect of Dasatanib on platelet and (F)
monocyte recruitment to TGF-b1 stimulated endothelial cells. Dasatanib (4 lmol/L) was added to blood 15 min prior to perfusion across EC
and the level of monocyte and platelet adhesion assessed by phase contrast microscopy (n = 4). Data are mean  SD. *P < .05, **P < .01, vs
ADP only control (C, D) vs blood perfused in the absence of Dasatanib (E, F) using one-way ANOVA followed by a Dunnett’s post-test
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differ in magnitude in wild type or SFK knockout animals. However,
upon super perfusion of ADP across rolling platelets, dramatic
differences in platelet function were evident. Wild type platelets
became rapidly activated and spread on the adhesive substrate
forming microthrombi (Figure 3A,D). Lyn/ platelets did not
become activated, and were washed from the system as they
rolled on the VWF substrate (Figure 3B,D). Fgr/ platelets showed
an intermediate phenotype, becoming stationary adherent on the
VWF, but failing to fully activate, spread or form aggregates
(Figure 3C,D).
The acquisition of such a profound phenotype in single SFK
knockout animals prompted us to determine whether the expression
of P-selectin from a-granules, which would be required the
thrombo-inflammatory secondary recruitment of monocytes, was
also affected in animals deficient in a single SFK isoform. In both
Lyn/ and Fgr/ platelets, P-selectin expression was dramatically
reduced in the presence of ADP (Figure 3E,F). Indeed, the levels of
inhibition of degranulation (and therefore P-selectin expression) were
not dissimilar to that seen in wild type platelets pre-treated with
disatanib (Figure 2B,D).
F IGURE 3 Mice deficient in Fgr or Lyn demonstrate decreased platelet activation, P selectin expression and leucocyte recruitment to VWF
under flow conditions. A, Representative images of WT (B) Lyn/ or (C) Fgr/ platelets activated with 30 lmol/L ADP on a matrix of
immobilized VWF in the presence of cells; (D) Average platelet coverage from flow (1000s) on a matrix of immobilized VWF in the presence
of 30 lmol/L ADP. The level of platelet adhesion was assessed by fluorescent microscopy. Data are mean  SEM. compared to WT (C57Bl6)
ADP positive controls (n = 15). E, Representative flow cytometry plot and (F) MFI  SD of P-selectin expression on WT, Lyn/ or Fgr/
platelets in response to ADP (n = 3). G, Number of WT monocytes adhering to Lyn/ or (H) Fgr/ platelets under flow conditions (100s).
The level of monocyte was adhesion assessed by phase contrast microscopy (n = 18). Data are mean  SEM. Data are shown as mean  SD.
*P < .05, **P < .01 compared to the WT ADP positive control using one-way ANOVA followed by a Dunnett’s post-test
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Because the effects of knocking out single SFK isoforms on
platelet function were so profound, we tested whether these
extended to the secondary, thrombo-inflammatory recruitment of
monocytes. To do this we established populations of wild type,
Fgr/ or Lyn/ platelets on immobilized VWF. Following activa-
tion by ADP, we perfused isolated murine monocytes across the
activated platelets. The secondary recruitment of wild type leuco-
cytes by ADP stimulated Lyn/ platelets was dramatically (>60%)
reduced, when compared to recruitment by WT platelets (Fig-
ure 3G). A similar but less robust inhibition of leucocyte recruit-
ment was evident when Fgr/ platelets were compared to wild
type (Figure 3H).
The use of an ex vivo adhesion assay also allowed us to deter-
mine whether the loss of SFK signalling in leucocytes was redundant
in the process of recruitment, as recently indicated by Kovacs et al35
In fact, when we used mononuclear leucocytes isolated from the
Lyn/ or the Fgr/ strains, and measured the levels of their
recruitment by wild-type platelets, we observed significant reduc-
tions in the efficiency of secondary recruitment in both the Lyn/
and the Fgr/ deficient leucocytes, strongly implying that
non-redundant SFK pathways supporting thrombo-inflammatory
recruitment of monocytes were also operative in leucocytes (Sup-
porting information Figure S4).
3.3 | Genetic deletion of single SFK isoforms in
mice dramatically reduces the burden of disease in
the ApoE/ model of atherosclerosis
The efficiency with which single SFK knockouts could inhibit both
platelet function and the secondary recruitment of monocytes in
ex vivo assays leads to the important conclusion that such molecules
represent therapeutic targets in thrombo-inflammatory pathways of
vascular disease. Such a supposition needed to be tested using inte-
grated in vivo models of disease which would stringently probe the
degree of redundancy in SFK signalling at a systemic level, and
would also establish whether signalling pathways additional to SFK
could support pathways of platelet and leucocyte activation in com-
plex multicellular process supporting disease pathogenesis. In this
context crossing the Lyn/ or Fgr/ knockout strains with the
ApoE/ model of atherosclerosis provide an ideal test of this
hypothesis. Moreover, using whole body SFK knockouts, these mod-
els have the benefit that they replicate the systemic effects (ie mul-
ti-cellular targets) of pharmacological agents targeting specific SFK
isoforms.
Total platelet count and percentage circulating peripheral blood
lymphocytes (PBL), monocytes (Mono) and neutrophils (PMN) did
not vary between ApoE/ Lyn/ and ApoE/ Fgr/ deficient
F IGURE 4 Decreased plaque burden in
the aortas of ApoE/ mice on HFD for
6 wk after Fgr and Lyn abolition. A, Plaque
burden in the aortas of Apoe/ animals or
ApoE/ mice deficient in Fgr or Lyn
assessed using analysis of oil red O
staining after 6 wk of HFD (n = 10-12). B,
False colour masks depicting plaque
burden in the aortas of Apoe/ animals or
ApoE/ mice deficient in Fgr or Lyn. C,
Site specific analysis of plaque burden
within the aorta (n = 10-12). Data are
mean  SEM *P < .05, **P < .01 ApoE/
Fgr/ and ApoE/ Lyn/ mice compared
to ApoE/ using one-way ANOVA
followed by a Dunnett (A) or Bonferroni
(B) post-test
8 | HARRISON ET AL.
mice and ApoE/, Lyn+/+ and Fgr+/+ controls (Supporting informa-
tion Table S1). ApoE/ animals fed a high fat diet (HFD) for
6 weeks demonstrated a significant level of plaque formation equiv-
alent to 15% plaque coverage over the whole aorta (Figure 4A,B).
Interestingly, the loss of either Lyn or Fgr led to a dramatic decrease
in disease burden over the whole aorta (Figure 4A,B; >70% and 60%
reduction in plaque coverage, respectively). Detailed analysis of the
anatomically distinct regions of the aorta and the major branching
arteries of the aortic arch, showed that disease was reduced uni-
formly across the arterial tree (Figure 4C). Interestingly, in both the
Lyn//ApoE/ and Fgr//ApoE/ strains both the number and
the average size (Figure 5A,B) of atheromatous lesions was signifi-
cantly reduced. Finally, we observed no significant differences in the
percentage of collagen content and cellularity in the plaque of all
groups analysed indicating that although plaque size was sensitive to
SFK knockout, the phenotype of the plaques did not vary (Support-
ing information Figure S5).
4 | DISCUSSION
Direct evidence that thrombo-inflammatory pathways are relevant to
the development of vascular disease comes from murine models of
atherosclerosis, where inhibition of platelet adhesion, or induction of
thrombocytopenia, significantly reduced the burden of ather-
oma.5,36,37 In addition, instillation of activated platelets exacerbates
arterial disease in such models.5 There is also direct evidence that
platelet P-selectin plays a role in plaque formation in the ApoE/
mouse.38,39 Other studies demonstrate that platelet-derived
chemokines such as CCL5 can selectively recruit monocytes in these
models.40,41 In addition the preferential recruitment of monocytes to
TGF-b1 stimulated EC in vitro and in vivo is mediated by platelet
bridges.6 TGF-b1 promotes the expression of a matrix of VWF on
the EC surface which recruits platelets from flowing blood. Upon
platelet activation at the EC surface by ADP, monocytes are in turn
recruited by platelet P-selectin.6,42 Experiments such as these, that
show the marked effects of modulating thrombo-inflammation, indi-
cate that interruption of these pathways may have utility in regulat-
ing the cellular pathology of diseases such as atherosclerosis.
Moreover, this could be an important target for such diseases, as
thrombo-inflammatory pathways may well fall without the control of
more conventional therapies for regulating inflammation in other
diseases.
The efficacy of knocking out a single SFK in such experiments is
interesting, particularly so as it is not even necessary to target the
most highly expressed SFK to modulate the activation of platelets in
these physiological assays. In murine platelets, the predominant SFKs
expressed in order of their abundance are Lyn, Src, Fyn and Fgr.43
Indeed the 2 SFK targeted in the current study (Lyn and Fgr) show
nearly a 100-fold differential in expression in platelets.43 Interest-
ingly, the responses to activation of platelets from the Fgr/ and
Lyn/ animals were distinct, demonstrating that these SFK regulate
different pathways downstream of activation with ADP. However, it
would appear that both pathways must be integrated for efficient
platelet activation, spreading and P-selectin expression and impor-
tantly, their functions are not redundant.
In the context of thrombo-inflammatory pathways of monocyte
recruitment in atheromatous disease, it appears that SFK play a
critical role in disease progression. Undoubtedly, the most unex-
pected, and thus the most interesting aspect of our studies has
been the ability to demonstrate that SFK signalling is not redundant
when physiologically exacting models of platelet and leucocyte
function are used to probe these pathways. Non-redundant func-
tions of SFK have previously been observed, for example in the
central nervous system. However, in this study the activity of Fyn
was involved in signal transduction from a single membrane recep-
tor (NCAM-140) feeding back on the process of neuronal migra-
tion.20 In the immune system and during an inflammatory response,
multiple adhesion and activation receptors feed into the leucocyte
trafficking process, and it is assumed that redundancy occurs due
to the number of alternative routes by which recruitment can be
facilitated. Thus, it is important to appreciate that even in a process
F IGURE 5 Decreased size and number of plaques in the
descending aorta of ApoE/ mice on HFD for 6 wk after Fgr and
Lyn abolition. A, B, ApoE/ mice that were WT or deficient in Fgr
or Lyn were placed on a HFD at 6 wk of age for a total of 6 wk.
Total number of individual plaques (A) or average plaque size (B) in
the descending aorta was analysed (n = 10-12 per group). *P < .05,
ApoE/ Fgr/ and ApoE/ Lyn/ mice compared to ApoE/
using one-way ANOVA followed by a Dunnett (A) post-test
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involving multiple cell types (here, monocytes, platelets and
endothelial cells), in a paradigm requiring multiple interactions
between adhesion and activation pathways, the loss of function of
a single SFK can have dramatic moderating effects on disease bur-
den in integrated models of arterial disease. These benefits appear
to be achievable without undue influence on the haemostatic and
immune systems, as no significant bleeding phenotypes are reported
in the single SFK knockout strains.43 Certainly, we observed no
excess morbidity or mortality in our own SFK knockout cohorts
over the duration of these experiments when compared to wild
type or ApoE/ control animals. In addition, we observed no
changes in plaque stability in these animals as collagen content and
cellularity did not differ between the groups. This is interesting as
it implies that targeting single SFK’s therapeutically would not result
in detrimental changes in plaque morphology that might lead to an
increased risk of thrombotic complications. Thus, we believe that
developing specific inhibitors to SFK isoforms is a rational approach
to targeting disease pathways.
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